Elanco Animal Health (ELAN) Current Deferred Revenue (2017 - 2026)

Elanco Animal Health has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $400.0 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $400.0 million, up 25.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $400.0 million (up 25.39% YoY), and the FY2025 annual result was $416.0 million, up 25.3% from the prior year.
• Current Deferred Revenue came in at $400.0 million for Q1 2026 at Elanco Animal Health, down from $416.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $416.0 million in Q4 2025 to a low of $284.0 million in Q2 2022.
• The 5-year median for Current Deferred Revenue is $332.0 million (2023), against an average of $341.8 million.
• Across the five-year window, Current Deferred Revenue declined 10.27% in 2022 and gained 25.39% in 2026, its largest moves.
• Elanco Animal Health's Current Deferred Revenue stood at $324.0 million in 2022, then rose by 13.27% to $367.0 million in 2023, then dropped by 9.54% to $332.0 million in 2024, then rose by 25.3% to $416.0 million in 2025, then fell by 3.85% to $400.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $400.0 million (Q1 2026), $416.0 million (Q4 2025), and $376.0 million (Q3 2025), per Business Quant data.